This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Myriad Genetics

And now for an update to the Biotech Stock Mailbag Readers' Portfolio (BSMRP), which is in serious need of a pick-me-up.

One quarter since inception, the BSMRP is down 8% compared to an almost 9% increase in the benchmark iShares Nasdaq Biotechnology ETF. (I tracked performance through the close of trading on March 30.)

Frankly, that's lousy stock picking, my dear readers, especially considering how hot the biotech sector has been this quarter. The cause of the problem is easy to diagnose: The BSMRP is overweight too many high-risk, small-cap biotech stock picks that have blown up.

BSMRP component GenVec (GNVC) is down 54% after a futility analysis forced the company to halt its phase III study of pancreatic cancer drug TNFerade. The GenVec loss is even more painful because the stock had been the best performer in the portfolio with a return exceeding 70%.

The other big losers in the portfolio: Cell Therapeutics (CTIC) is down 47% following the negative FDA panel vote for its cancer drug pixantrone; MannKind (MNKD) is down 34% on more approval delays for its inhaled insulin device; and Novelos Therapeutics (NVLT.OB) is essentially a corpse, down 89%, after its lung cancer drug failed a phase III study.

Recall, the BSMRP is a portfolio of 20 biotech and drug stocks chosen by readers of the Biotech Stock Mailbag. The 20 stocks in the portfolio were winnowed from a master list of 93 different stocks nominated by readers in December and January.
3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
QCOR $93.60 1.65%
CTIC $0.34 0.00%
ACUR $2.17 0.00%
CLDX $7.25 0.00%
MYGN $34.21 0.00%


Chart of I:DJI
DOW 15,973.84 +313.66 2.00%
S&P 500 1,864.78 +35.70 1.95%
NASDAQ 4,337.5120 +70.6750 1.66%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs